mosunetuzumab,rituximab,lenalidomide
roche,biogen
['mosunetuzumab', 'lymsm', 'rituximab', 'lymphoma']
congress| #eha2022 , outlines the celestimo phase 3 trial which evaluates the efficacy and safety of mosunetuzumab-lenalidomide versus rituximab plus lenalidomide in patients with previously treated r/r fl #lymphoma #lymsm #medicalcongress 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm